An interventional study of sleeve gastrectomy with transit bipartition (SG +TB) and Roux-en-Y gastric bypass (RYGB) in Severe Obesity, sponsored by University Hospital, Lille. Completed at 8 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Obesity, Morbid with a site in France — 13 open to participants now, 15 under way, none of them phase 3. Obesity, Morbid · France.
Among the 66 studies in Obesity, Morbid with a site in France, this one is the 8th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2021, is one of 36 with no phase, and was the 52nd registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →13 of the 66 studies in Obesity, Morbid with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Metropole Savoie · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–70
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–59
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 320 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 100 across the 42 interventional studies, 170 across the 23 observational. Of the 44 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 66 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 2 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
6 of the studies in Obesity, Morbid with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02310178University Hospital, MontpellierObesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery | 2026-12 |
| NCT02811900IHU StrasbourgAn Evaluation of the Outcomes of Bariatric Surgery - a Cohort Study | 2026-12 |
| NCT03517072University Hospital, LilleDeterminants of the Long-Term Success of Bariatric Surgery | 2027-01 |
| NCT06133413Assistance Publique - Hôpitaux de ParisConnected Scales to Optimize the Maintenance of Weight Lost After Bariatric Surgery and Limit Failures and Reoperations | 2027-02 |
| NCT06119516Assistance Publique - Hôpitaux de ParisTranspulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. | 2027-04-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 66 studies in Obesity, Morbid with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Sleeve Gastrectomy (SG) has become the most performed intervention either worldwide or in France, where SG represents more than 60% of bariatric interventions and 114,817 patients operated between 2013 and 2016.
Maximum Excess weight loss (%EWL) after SG is obtained at one-year post surgery. Then it has been largely reported in the literature that patients could present mild, moderate or important (notably in the super obese patients) weight regain associated with comorbidity relapse motivating redo surgery. Like in revisional surgery, operating super-obese patient (BMI ≥50 kg/m2) is a challenge. It has been shown that achieving significant weight loss was more difficult in patients with a BMI ≥ 50 compared to lower BMIs.
In these 2 populations of patients, more malabsorptive procedures like long limb One Anastomosis Gastric Bypass or Bilio-Pancreatic Diversion with Duodenal Switch could be more efficient but induce technical difficulties (high complication rate) and can be responsible for malnutrition (vitamin deficiencies, hypoalbuminemia…). That's why, in case of revisional surgery or for high BMI patients,laparoscopic Roux-en-Y gastric bypass (RYGBP) is still considered as the gold standard and is the most performed intervention. To obtain better weight loss safely,Santoro et al. promoted the sleeve gastrectomy with transit bipartition (SG+TB), a new intervention coupling a SG without interrupting pathway through the duodenum and preserving the pylorus and a long biliary limb RYGBP.
Hypothesis: Because there is no duodenal and jejunal exclusion, malnutrition is expected to be less frequent after SG+TB compared to BPD/DS. Its anastomosis on the antrum makes SG+TB easier to perform in super-obese patient than standard RYGB but more efficient in term of weight loss. Compared to BPD/DS or SADI which involves dissection of the duodenum and the confection of a duodenojejunostomy, SG+TB is also expected to be easier then safer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
Procedure: sleeve gastrectomy with transit bipartition (SG +TB)
One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
Procedure: Roux-en-Y gastric bypass (RYGB)
In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
The Excess Weight Loss percentage (EWL%)
The Excess Weight Loss percentage (EWL%) calculated with the following formula: ((weight at 2 years visit - initial weight (kg)) / (initial weight - ideal weight)) X 100 Ideal weight defined as the weight corresponding to a BMI = 25 kg/m2. Initial weight defined as preoperative weight at V1. All weights are expressed in kg
Time frame: at 2 years after surgery
Change nutritional status assessment
Nutritional profil : Hemoglobin (g/l), albumin (g/l), prealbumin (g/l)
Time frame: from baseline (before surgery) to 24 months after surgery
Change in liver status assessment
Liver parameters ( ALT AST GGT Alkaline phosphatases, Total bilirubin, prothrombin time, urea, creatininemia concentration)
Time frame: from baseline (before surgery) to 24 months after surgery
Change in vitamins status assessment
vitamins profil (vitamin A B1, B6 B9, B12, C , D and E concentration)
Time frame: from baseline (before surgery) to 24 months after surgery
Change in mineral status assessment
Mineral profil ( ferritin, potassium, calcium,iron, transferrin, magnesium, selenium, zinc phophore concentration)
Time frame: from baseline (before surgery) to 24 months after surgery
24-hour steatorrhea quantified at 6 months
24-hour steatorrhea is assessed to evaluate denutrition, expressed in g of lipid/24hr
Time frame: At 6 months
Evolution of muscle mass assessed by bioelectrical impedance analysis
muscle mass is assessed to evaluate denutrition.
Time frame: from baseline to 24 months after surgery
Evolution of muscle mass assessed by grip strength test.
muscle mass is assessed to evaluate denutrition.
Time frame: from baseline to 24 months after surgery
Complications rate within 2 years according to Dindo-Clavien classification
complications rate is assessed to evaluate safety of the procedure
Time frame: within 2 years
Length of hospital stay defined as the number of days of hospitalization
length of hospital stay for the surgical procedure
Time frame: up to 2 week
Evolution from baseline to 24 months after surgery of HbA1c level, HDL, LDL and triglycerides
Evolution from baseline to 24 months after surgery of HbA1c level (expressed in %), fasting glycemia (expressed in mmol/l or g/l), HDL (expressed in mmol/l or g/l), LDL (expressed in mmol/l or g/l) and triglycerides (expressed in mmol/l)
Time frame: from baseline to 24 months after surgery
Evolution from baseline to 24 months of insulinoresistance defined by HOMA-IR calculated with fasting blood glucose and fasting insulinemia12
assessment of insulinoresistance
Time frame: from baseline to 24 months
Change of the GIQLI score
This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to patients and for each answer, a score is assigned, ranging from 0 to 4 (highest score = 144). A high score defines a more favorable health state
Time frame: from baseline to 24 months after surgery
Change of the SF36 scores
This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health.
Time frame: from baseline to 24 months after surgery
Change in Sigstad questionnaire score (dumping syndrome).
The Sigstad questionnaire allows the identification and diagnosis of postoperative hypoglycemia: a score \> 7 suggests a dumping and a score \<4 suggests another diagnosis. Complementary questions regarding timing of dumping (\<30 min or \>1h30) will be asked if Sigstad score \>7.
Time frame: from baseline to 24 months after surgery
Change of food choices and preferences assessed by the Leeds Food Preference Questionnaire (LFPQ) score.
The Leeds Food Preference Questionnaire provides measures of different components of food preference and food reward. Participants are presented with an array of pictures of individual food items common in the diet. Foods in the array are chosen by the experimenter from a validated database to be either predominantly high (\>50% energy) or low (\<20% energy) in fat but similar in familiarity, protein content, sweet or non-sweet taste and palatability. Outcome measured are explicit Liking, explicit wanting, implicit wanting and food choice. Scores for explicit liking and explicit wanting range from 0-100 with a typical mean (±S.D.) of 60±18 Scores for Food Choice range from 0-48 and have a typical mean of 24±10 or for the appeal bias range from -48-48 with a typical mean of -5±15. Scores for Implicit Wanting typically range from -100-100 (due to RT there is no fixed min-max value) and have a typical mean of ±10±25 or for the appeal bias a typical mean of -10±30.
Time frame: from baseline to 24 months after surgery
Change of physical activity assessed by the International Physical Activity Index (IPAQ) score.
The International Physical Activity Questionnaire assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives to estimate total physical activity in MET-min/week and time spent sitting.
Time frame: from baseline to 24 months after surgery
Ran from Jul 2021 to primary completion in May 2026, 57 months.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 57 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jul 2026 → May 2026 and completion Jul 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.